Genomic Health Announces Second Quarter 2012 Financial Results and Business Progress
- Product Revenue Increased 13% Compared with Prior Year
- Delivered Net Income of $1.8 Million
- Began Offering Oncotype DX® Colon Cancer Test for Stage III Patients
- Combined Invitae with Locus Development to Create Independent Genetics Company
- Conference Call Today at 4:30 p.m. ET
REDWOOD CITY, Calif., Aug. 8, 2012 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June ...
